Security
BEAM · Beam Therapeutics Inc.
BEAMNASDAQCommon stockCurrentCIK 1745999Updated Sep 27, 2026
Name history
Beam Therapeutics Inc. · through Sep 25, 2026
BEAM price & chart
Loading TradingView…
NASDAQ:BEAM on TradingView ↗About the company
Beam Therapeutics (Nasdaq: BEAM) is a biotechnology company committed to establishing the leading, fully integrated platform for precision genetic medicines. To achieve this vision, Beam has assembled a platform with integrated gene editing, delivery and internal manufacturing capabilities. Beam’s suite of gene editing technologies is anchored by base editing, a proprietary technology that is designed to enable precise, predictable and efficient single base changes, at targeted genomic sequences, without making double-stranded breaks in the DNA. This has the potential to enable a wide range of therapeutic editing strategies that Beam is using to advance a diversified portfolio of base editing programs. Beam is a values-driven organization committed to its people, cutting-edge science, and a vision of providing lifelong cures to patients suffering from serious diseases.
In the news
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Beam Therapeutics Inc. - BEAM ↗
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Beam Therapeutics Inc. - BEAM ↗
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Beam Therapeutics Inc. - BEAM ↗
Recent filings
SCHEDULE 13G/A filing
10-Q filing
Results of Operations and Financial Condition
Items 2.02, 9.01
144 filing
4 filing
Show 5 more recent filings
Financials
FY 2025 · USDSource
Source
Source
Source
Source
Source
balance sheet · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| ASSETS | ||||
| AssetsUSD | 1,481,177,000Source | 1,103,824,000Source | 1,459,714,000Source | 1,341,714,000Source |
| Property, Plant and Equipment, NetUSD | 104,500,000Source | 111,412,000Source | 124,960,000Source | 115,620,000Source |
| Current assets: | ||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 294,944,000Source | 281,967,000Source | 435,895,000Source | 232,767,000Source |
| Assets, CurrentUSD | 1,268,688,000Source | 878,149,000Source | 1,211,043,000Source | 1,092,896,000Source |
| Prepaid Expense and Other Assets, CurrentUSD | 23,478,000Source | 27,409,000Source | 21,167,000Source | 14,762,000Source |
| Operating Lease, Right-of-Use AssetUSD | 100,679,000Source | 104,865,000Source | 112,846,000Source | 118,513,000Source |
| Other Assets, NoncurrentUSD | 634,000Source | 1,254,000Source | 2,146,000Source | 1,931,000Source |
| LIABILITIES AND EQUITY | ||||
| LiabilitiesUSD | 242,819,000Source | 370,279,000Source | 478,385,000Source | 608,240,000Source |
| Stockholders’ equity: | ||||
| Common Stock, Value, IssuedUSD | 1,017,000Source | 836,000Source | 816,000Source | 712,000Source |
| Additional Paid in CapitalUSD | 2,877,449,000Source | 2,298,661,000Source | 2,169,798,000Source | 1,792,554,000Source |
| Retained Earnings (Accumulated Deficit)USD | -1,641,219,000Source | -1,566,631,000Source | -1,189,889,000Source | -1,057,362,000Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | 1,111,000Source | 679,000Source | 604,000Source | -2,430,000Source |
| Stockholders' Equity Attributable to ParentUSD | 1,238,358,000Source | 733,545,000Source | 981,329,000Source | 733,474,000Source |
| Liabilities and EquityUSD | 1,481,177,000Source | 1,103,824,000Source | 1,459,714,000Source | 1,341,714,000Source |
| Current liabilities: | ||||
| Liabilities, CurrentUSD | 96,935,000Source | 182,066,000Source | 205,565,000Source | 223,595,000Source |
| Operating Lease, Liability, CurrentUSD | 14,364,000Source | 13,469,000Source | 12,778,000Source | 10,380,000Source |
| Accounts Payable, CurrentUSD | 10,231,000Source | 3,871,000Source | 1,617,000Source | 9,029,000Source |
| Operating Lease, Liability, NoncurrentUSD | 139,759,000Source | 147,956,000Source | 159,911,000Source | 168,625,000Source |
| Other Liabilities, NoncurrentUSD | 173,000Source | 504,000Source | 298,000Source | 224,000Source |
| Additional Financial Items | ||||
| Cash, Cash Equivalents, and Short-term InvestmentsUSD | 1,200,000,000Source | 850,700,000Source | 1,200,000,000Source | 1,100,000,000Source |
cash flow · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Cash flows from operating activities: | ||||
| Net Income (Loss), Including Portion Attributable to Noncontrolling InterestUSD | -79,992,000Source | -376,742,000Source | -132,527,000Source | -289,088,000Source |
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||
| Depreciation, Depletion and AmortizationUSD | 22,294,000Source | 21,925,000Source | 20,012,000Source | 14,147,000Source |
| Share-based Payment Arrangement, Noncash ExpenseUSD | 94,244,000Source | 120,662,000Source | 98,647,000Source | 84,321,000Source |
| Changes in operating assets and liabilities: | ||||
| Increase (Decrease) in Accounts PayableUSD | 6,040,000Source | 1,807,000Source | -7,578,000Source | 2,373,000Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | -345,102,000Source | -347,246,000Source | -149,195,000Source | 22,527,000Source |
| Cash flows from investing activities: | ||||
| Payments to Acquire Businesses, Net of Cash AcquiredUSD | 78,000Source | — | — | — |
| Net Cash Provided by (Used in) Investing ActivitiesUSD | -121,438,000Source | 185,007,000Source | 71,840,000Source | -461,336,000Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | 14,946,000Source | 8,946,000Source | 33,732,000Source | 48,951,000Source |
| Cash flows from financing activities: | ||||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | 478,049,000Source | 7,736,000Source | 276,448,000Source | 111,590,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | 11,509,000Source | -154,503,000Source | 199,093,000Source | -327,219,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | 301,620,000Source | 290,111,000Source | 444,614,000Source | 245,521,000Source |
| Supplemental disclosure of cash flow information: | ||||
| Interest Paid, Excluding Capitalized Interest, Operating ActivitiesUSD | 0Source | 32,000Source | 160,000Source | 376,000Source |
| Additional Financial Items | ||||
| Share-based Payment Arrangement, ExpenseUSD | 94,244,000Source | 120,662,000Source | 98,647,000Source | 84,321,000Source |
| Cash, Cash Equivalents, and Short-term InvestmentsUSD | 1,200,000,000Source | 850,700,000Source | 1,200,000,000Source | 1,100,000,000Source |
| DepreciationUSD | 22,294,000Source | 21,925,000Source | 20,012,000Source | 14,097,000Source |
| Derivative, Gain (Loss) on Derivative, NetUSD | 700,000Source | 2,272,000Source | 7,500,000Source | 23,900,000Source |
| Equity Method Investment, Realized Gain (Loss) on DisposalUSD | 255,146,000Source | — | — | — |
| Equity Securities, FV-NI, Gain (Loss)USD | 3,942,000Source | -14,093,000Source | -18,592,000Source | 20,200,000Source |
| General and Administrative ExpenseUSD | 113,818,000Source | 111,525,000Source | 116,813,000Source | 87,805,000Source |
| Income (Loss) from Equity Method InvestmentsUSD | 255,146,000Source | — | — | -25,500,000Source |
| Income Tax Expense (Benefit)USD | 0Source | 39,000Source | 1,366,000Source | 3,410,000Source |
| Marketable Securities, Realized Gain (Loss), Excluding Other-than-temporary Impairment LossUSD | -399,000Source | 0Source | — | — |
| Net Income (Loss) Attributable to ParentUSD | -79,992,000Source | -376,742,000Source | -132,527,000Source | -289,088,000Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | -79,992,000Source | -376,742,000Source | -132,527,000Source | -289,088,000Source |
| Nonoperating Income (Expense)USD | 303,701,000Source | 38,865,000Source | 45,324,000Source | 78,301,000Source |
| Operating ExpensesUSD | 523,436,000Source | 479,086,000Source | 554,194,000Source | 399,399,000Source |
| Proceeds from Issuance of Common StockUSD | — | — | 236,568,000Source | 108,258,000Source |
| Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-saleUSD | 842,489,000Source | 680,392,000Source | 1,089,910,000Source | 1,204,614,000Source |
| Proceeds from Stock Options ExercisedUSD | 4,772,000Source | 5,600,000Source | 6,131,000Source | 2,732,000Source |
income statement · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Total RevenueUSD | 139,743,000Source | 63,518,000Source | 377,709,000Source | 60,920,000Source |
| Operating Income (Loss)USD | -383,693,000Source | -415,568,000Source | -176,485,000Source | -338,479,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | -79,992,000Source | — | — | -260,178,000Source |
| Income Tax Expense (Benefit)USD | 0Source | 39,000Source | 1,366,000Source | 3,410,000Source |
| Net Income (Loss) Attributable to ParentUSD | -79,992,000Source | -376,742,000Source | -132,527,000Source | -289,088,000Source |
| Earnings Per Share, BasicUSD per share | -0.81Source | -4.58Source | -1.72Source | -4.13Source |
| Earnings Per Share, DilutedUSD per share | -0.81Source | -4.58Source | -1.72Source | -4.13Source |
| Weighted Average Number of Shares Outstanding, Basicshares | 98,905,577Source | 82,313,008Source | 77,151,771Source | 70,015,305Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | 98,905,577Source | 82,313,008Source | 77,151,771Source | 70,015,305Source |
| Additional Financial Items | ||||
| Current Income Tax Expense (Benefit)USD | 0Source | 100,000Source | 1,400,000Source | — |
| Depreciation, Depletion and Amortization, NonproductionUSD | 22,294,000Source | 21,925,000Source | — | — |
| General and Administrative ExpenseUSD | 113,818,000Source | 111,525,000Source | 116,813,000Source | 87,805,000Source |
| Income (Loss) from Equity Method InvestmentsUSD | 255,146,000Source | — | — | -25,500,000Source |
| Interest and Other IncomeUSD | 43,733,000Source | 49,094,000Source | — | — |
| Marketable Securities, Realized Gain (Loss), Excluding Other-than-temporary Impairment LossUSD | -399,000Source | 0Source | — | — |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | -79,992,000Source | -376,742,000Source | -132,527,000Source | -289,088,000Source |
| Nonoperating Income (Expense)USD | 303,701,000Source | 38,865,000Source | 45,324,000Source | 78,301,000Source |
| Operating ExpensesUSD | 523,436,000Source | 479,086,000Source | 554,194,000Source | 399,399,000Source |
| Research and Development ExpenseUSD | 409,618,000Source | 367,561,000Source | 437,381,000Source | 311,594,000Source |
| Restructuring and Related Cost, Incurred CostUSD | 0Source | — | — | — |
Filing attachments
beam-ex99_1.htm · 8-K · 2026-08-04
EX-99.1 2 beam-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Beam Therapeutics Reports Second Quarter 2026 Financial Results and Announces First Patient Dosed in Global Pivotal Cohort of BEAM-302 Trial in Alpha-1 Antitrypsin Deficiency (AATD) Updated BEAM-302 Phase 1/2 Clinical Data Selected for Late-Breaking Oral Presentation at the European Respiratory Society (ERS) Congress 2026 Dosing Complete for All Adult and Adolescent Patients in Phase 1/2 BEACON Trial of Risto-cel in Sickle Cell Disea…
Read attachment ↗beam-ex99_1.htm · 8-K · 2026-05-07
EX-99.1 2 beam-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Beam Therapeutics Reports First Quarter 2026 Financial Results and Recent Business Updates Recent BEAM-302 Topline Data in Alpha-1 Antitrypsin Deficiency (AATD) Demonstrate Strong Single-dose Safety and Efficacy Profile, with 60 mg Selected as Optimal Biological Dose; Global Pivotal Cohort Expected to Initiate in Second Half of 2026 Data from Phase 1/2 BEACON Clinical Trial of Risto-cel in Sickle Cell Disease Published in April 1 Iss…
Read attachment ↗beam-ex99_1.htm · 8-K · 2026-02-24
EX-99.1 2 beam-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Beam Therapeutics Reports Fourth Quarter and Year-End 2025 Financial Results and Announces New Liver-Targeted Genetic Disease Program in Phenylketonuria (PKU) New Program Designed as Platform-based Approach for Direct Correction of Mutations Causing PKU; Investigational New Drug (IND) Filing for BEAM‑304 Anticipated in 2026 Updated Phase 1/2 Data and Next Steps for Pivotal Development for BEAM-302 in Alpha-1 Antitrypsin Deficiency (A…
Read attachment ↗beam-ex99_1.htm · 8-K · 2026-01-12
EX-99.1 2 beam-ex99_1.htm EX-99.1 EX-99.1 Beam Therapeutics Sets Strategic Priorities for its Genetic Disease and Hematology Franchises to Drive Execution of Late-Stage Clinical Programs and Extends its Operating Runway through Commercial Transition Alignment Reached with U.S. FDA on Potential Accelerated Approval Pathway for BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) Based on Biomarker Endpoints U.S. Biologics Licensing Application (BLA) Submission for risto-cel (Previously Known …
Read attachment ↗beam-ex99_2.htm · 8-K · 2026-01-12
EX-99.2 3 beam-ex99_2.htm EX-99.2 The Power of Predictability JANUARY 2026 NASDAQ: BEAM Cautionary note regarding forward-looking statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include statements regarding: the therapeutic applications and potential of our technology, including with respect to SCD, AATD, GSDIa and beta-thalassemia; our plans, and anticipated timing,…
Read attachment ↗beam-ex99_1.htm · 8-K · 2025-11-04
EX-99.1 2 beam-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Beam Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business Updates Expanded Dose Exploration in Part A and Dose Escalation in Part B of BEAM-302 Phase 1/2 Study in Alpha-1 Antitrypsin Deficiency Ongoing; Updated Data and Clinical Development Update Expected in Early 2026 Updated Data from BEACON Phase 1/2 Trial of BEAM-101 in Sickle Cell Disease Accepted for Presentation at American Society of Hematology (ASH)…
Read attachment ↗